Some providers featured on this site may compensate us. This may affect the order and placement of listings but does not influence our editorial ratings or reviews.
Treatments Hub

Verified prices

All verified prices
Science6 min read

Zepbound vs Wegovy: Comparing the Two FDA-Approved Weight Loss Drugs

Zepbound and Wegovy are both FDA-approved for weight loss but use different mechanisms. Here's how they compare on results, side effects, cost, and availability.

Updated September 15, 2026

Medically reviewed on

How we review

The quick answerBoth are FDA-approved for weight loss, but they are different drugs: Zepbound (tirzepatide) targets two hormone receptors and produced up to 22.5% average weight loss in trials versus ~15% for Wegovy (semaglutide). At verified prices, brand Zepbound runs $1,249/month at altRx (pens from $299 first month at ro); compounded routes start at $41-$99/month.Prices verified on each provider’s site as of November 3, 2026.

Both FDA-Approved for Weight Loss

Zepbound (tirzepatide) and Wegovy (semaglutide) are the only two GLP-1-based medications with specific FDA approval for chronic weight management. This sets them apart from Ozempic and Mounjaro, which are approved for diabetes but widely used off-label for weight loss. Having FDA approval for weight loss means these drugs went through rigorous clinical trials specifically measuring their effectiveness for weight management.

Our top 2 picks

Our two recommended GLP-1 providers, shown with the same verified pricing and ratings as our full comparison.

Our Top Pick
1
embody logo

Exceptional

9.8out of 10

Compounded GLP-1 from $49/month; not FDA-approved, free expedited delivery

Free expedited deliveryNo hidden fees
  • Compounded semaglutide ($49/mo) and tirzepatide ($99/mo) as shown on the homepage, Nov 16, 2026; not FDA-approved
  • Online intake, then a prescriber review by OpenLoop Health, a network of US-licensed doctors
  • Free expedited delivery (embody's words); the Terms do not guarantee a delivery timeline
  • No insurance required, no clinic visits; cancel at least 72 hours before the next billing date

from $49/month

Doctor-prescribed compounded GLP-1 treatment, not FDA-approved: semaglutide shown at $49/month and tirzepatide at $99/month on embody's homepage (Nov 16, 2026), no insurance required.

Read full embody review
2
altRx logo

Excellent

9.4out of 10

Most Comprehensive GLP-1 Medication Access

Transparent pricingNo insurance required
  • Compounded GLP-1 from $89/mo, GLP-1 + GIP from $149/mo
  • Brand-name options too: Zepbound and Wegovy
  • Clinician-guided - physician, PA, or nurse practitioner
  • Free shipping (about 5-7 days)

from $89/month

Affordable GLP-1 program from $89/month - compounded semaglutide and tirzepatide plus brand-name options - with clinician-guided, self-pay care and no insurance required.

Read full altRx review

How They Work Differently

Wegovy targets one receptor: GLP-1. Zepbound targets two: GLP-1 and GIP.

This dual-agonist approach gives Zepbound a broader metabolic effect. For a deeper explanation, see our article on how GLP-1 medications work and our tirzepatide vs semaglutide comparison.

Clinical Trial Results

Wegovy (STEP trials): ~15% average weight loss over 68 weeks. Zepbound (SURMOUNT trials): up to 22.5% average weight loss over 72 weeks. While these come from different trials and direct comparison requires caution, the trend is consistent - tirzepatide-based medications produce greater average weight loss in clinical research.

Cost and Insurance

Both are expensive at retail - Wegovy at $1,300-$1,400/month and Zepbound at $1,000-$1,100/month. Insurance coverage is limited for both.

Compounded alternatives through telehealth providers offer significant savings: compounded semaglutide from ~$200/month and compounded tirzepatide from ~$350/month. See our cost guide for details. Compare affordable options.

Shop GLP-1 plans by product

The lowest published plans - cheapest first, conditions under each price.

What To Know Before Starting GLP-1 Treatment

Before starting GLP-1 treatment, it's important to understand a few key things. These medications require a prescription from a licensed clinician and aren't suitable for everyone. Some people may experience side effects, especially during the first few weeks as the body adjusts.

GLP-1s also tend to work best when combined with basic lifestyle habits like balanced nutrition and regular physical activity.

That's why choosing a provider that offers proper medical screening and ongoing follow-up support is essential for both safety and long-term success.

Woman preparing GLP-1 weight loss injection

Which Is Right for You?

If you want the maximum weight loss potential and can access it, Zepbound has a clinical edge. If you prefer a longer track record, broader compounded availability, and slightly lower compounded pricing, Wegovy/semaglutide is the more established path. Many telehealth providers offer both - take our quiz to find the best match, or compare providers directly.

Dosing Schedule Compared

Wegovy titrates from 0.25 mg to 2.4 mg over about 16 weeks. Zepbound starts at 2.5 mg and can go up to 15 mg.

Both are once-weekly injections. Zepbound's wider dose range gives providers more room to optimize treatment.

For details on what starting either medication feels like, see our first month guide.

Compounded Alternatives

Both Wegovy (semaglutide) and Zepbound (tirzepatide) have compounded versions available through telehealth providers at significantly lower prices. Compounded semaglutide starts at ~$199/month, compounded tirzepatide at ~$349/month. Read our compounded vs brand-name guide for details on quality and safety.

How to Access Either Medication Online

Both are available through licensed telehealth providers without in-person visits. Compare semaglutide providers or tirzepatide providers. For a step-by-step walkthrough, see our guide to getting GLP-1 medications online.

Ready to compare weight loss providers?

See how top providers stack up on pricing, medical support, and treatment options.

Medical disclaimer

This page is general information about GLP-1 weight-loss medications such as semaglutide and tirzepatide, published to help you compare services. It is not medical advice, it does not create a doctor-patient relationship, and it is not a substitute for a consultation with a licensed clinician who knows your history. Treatments Hub is not a medical provider, pharmacy or clinic and does not prescribe, sell or dispense medication. Do not start, stop or change any treatment because of something you read here, and do not delay seeking care; in an emergency call 911.

Semaglutide and tirzepatide carry an FDA boxed warning about thyroid C-cell tumours seen in rodents and are not for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2, nor for use in pregnancy. Compounded versions sold by telehealth providers are prepared by state-licensed pharmacies and are not FDA-approved products. Where a review or post on this page mentions weight lost, that is one person's result and is not typical; results vary widely.

Medical and scientific statements on this site are checked against the sources linked on the page by our medical content reviewer, who does not choose providers or set prices. Prices, plans and customer reviews are each provider's published figures and customers' own words on the dates stated. We may earn a commission from provider links. The full medical and advertising disclaimer explains all of this in detail.

Sources & medical references

Treatment facts on this page are grounded in regulatory guidance and peer-reviewed research. Pricing and plan details come from each provider's published information. This content is for information only and is not medical advice - always consult a licensed clinician before starting treatment.

  1. 1.Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial) - New England Journal of Medicine, 2021
  2. 2.Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1 trial) - New England Journal of Medicine, 2022
  3. 3.FDA Approves New Drug Treatment for Chronic Weight Management (semaglutide / Wegovy) - U.S. Food & Drug Administration, 2021
  4. 4.FDA Approves New Medication for Chronic Weight Management (tirzepatide / Zepbound) - U.S. Food & Drug Administration, 2023
  5. 5.FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss - U.S. Food & Drug Administration
  6. 6.Human Drug Compounding (503A pharmacy standards) - U.S. Food & Drug Administration
  7. 7.Semaglutide Injection - drug information - MedlinePlus, U.S. National Library of Medicine (NIH)